| Three Months Ended June 30, 2025 (2024) | Six Months Ended June 30, 2025 (2024) |
| Revenue was SEK 9.3 M (8.0 M) | Revenue was SEK 19.1 M (14.1 M) |
| Operating profit/loss was SEK -25.9 M (-16.0 M) | Operating profit/loss was SEK -42.4 M (-29.7 M) |
| Net profit/loss was SEK -22.2 M (-19.7 M) | Net profit/loss was SEK -3.3 M (-29.0 M) |
| Cash and cash equivalent SEK 308.2 M (54.4) | Cash and cash equivalent SEK 308.2 M (54.4) |
| Basic earnings/loss per share was SEK -0.17 (-0.18) | Basic earnings/loss per share was SEK -0.03 (-0.29) |
| Diluted earnings/loss per share were SEK -0.17 (-0.18) | Diluted earnings/loss per share were SEK -0.03 (-0.29) |
Business highlights in Q2 2025
Significant events after the reporting period
Comments from the CEO
“Saniona has entered its next phase of growth. With two landmark partnerships in less than a year and a strong financial foundation, we are advancing our focused pipeline of innovative medicines toward key clinical milestones. The collaboration with Jazz Pharmaceuticals validates our R&D approach, secures progress of SAN2355, and provides the resources to independently advance SAN2219, SAN2465 and other internal programs into Phase 2. We are building a company with the potential to deliver transformative therapies in neurology and psychiatry while creating long-term value for our shareholders.”
Investor call
Saniona will host a Q2 investor call on 28 August 2025, at 13.00 CEST.
At the call Management will be presenting results and a company update. At the end of the presentation there will be a Q&A session, where participants can ask online questions.
Access to the event can be obtained through the following link:
Live Q: Saniona - Redeye
REPLAY access
Webcast replay will be available at www.saniona.com and at www.redeye.se